Sentence examples for the medium dose and from inspiring English sources

H&E staining of fixed lung sections from the different doses showed no signs of fibrosis at the low dose, very mild changes in the medium dose, and a similar extent and pattern of fibrosis as indicated in figure 3 for the high dose of 5 mg silica per mouse (Data not illustrated).

Compared with the control, the low dose produced 21.2% decrease, whilst the medium dose and the high dose produced 31.3% and 60.2% decrease in serum sPLA2 activity respectively.

All the doses of the roots extract produced significant increases in 6-keto PGF1α by 28.3% in the low dose, 61.7% in the medium dose and 88.6% in the high dose.

The degree of suppression was 26.7 ± 3.2% (P < 0.05) at the medium dose and 61.6 ± 3.4% (P < 0.01) at the high dose compared to the control on day 21.

The approximate oral equivalents for these olanzapine LAI dosages are 10 mg/day for the low dose, 15 mg/day for the medium dose, and 20 mg/day for the high dose.

In addition, there were no significant differences in the levels of CRP and PlGF between the COPD patients with the medium doses and those with high doses of ICS (Table 2).

A survival rate of 87.5% was found in the low-dose cohort, 62.5% in the medium-dose, and 0% in high-dose, Fig. 5a.

Furthermore, the mean renal absorbed dose for the medium-dose and the high-dose cohorts was 23 and 16 Gy, respectively.

Risk of AVN development in the medium-dose and higher-dose groups was compared to that in the lower-dose group.

In trunk kidney leukocytes increased chemiluminescence by luminol was observed in the fish fed the medium dose ZEN diet and increased chemiluminescence by lucigenin in the low dose ZEN-fed fish.

For both the rectum and bladder, a greater difference between f-SA and p-SA plans was observed at the medium dose levels of V40Gy and V50Gy (Davg: 16.9% to 29.5%) when compared with the high dose level at V70Gy (Davg: 8.6% to 10.3%) and low dose level at V20Gy (Davg: 6.1% to 18.8%).